Johnson & Johnson said its reported sales for Q1 2025 were $21,893 million, up 2.4% from $21,383 million a year earlier, and operational sales growth, which excludes the effect of currency translation, was 4.2%.

1. 01

   Johnson & Johnson said its reported sales for Q1 2025 were $21,893 million, up 2.4% from $21,383 million a year earlier, and operational sales growth, which excludes the effect of currency translation, was 4.2%.

2. 02

   Johnson & Johnson said Innovative Medicine sales for Q1 2025 were $13,873 million, up 2.3% on a reported basis, and MedTech sales were $8,020 million, up 2.5% on a reported basis. Operational growth was 4.2% and 4.1%, respectively.

3. 03

   The company set its 2025 full-year operational sales outlook at $91.6B to $92.4B (previously $90.9B to $91.7B) and kept its adjusted EPS outlook at $10.50 to $10.70. Its Board of Directors raised the quarterly dividend by 4.8%, from $1.24 to $1.30 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.